Phase II checkpoint inhibitor combination study of SCIB1 in melanoma patients

Trial Profile

Phase II checkpoint inhibitor combination study of SCIB1 in melanoma patients

Planning
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Checkpoint kinase inhibitors (Primary) ; SCIB 1 (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Sep 2017 According to Scancell media release, the company expected to submit an Investigational New Drug (IND) application for SCIB1 Phase 2 checkpoint inhibitor combination study in early 2018, with patient enrolment planned for 2018.
    • 11 Jul 2017 According to Scancell media release, the company is on track to submit the IND for this study in 3Q17.
    • 16 Sep 2016 According to Scancell media release, enrolment expected to commence in Q3 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top